Abstract:Aromatase is a member of the cytochrome P450 superfamily responsible for a key step in the biosynthesis of estrogens. As estrogens are involved in the control of important reproduction-related processes, including sexual differentiation and maturation, aromatase is a potential target for endocrine disrupting chemicals as well as breast cancer therapy. In this work, 3D-QSAR combined with quantitative profile of protein–ligand interactions was employed in the identification and characterization of critical steric and electronic features of aromatase-inhibitor complexes and the estimation of their quantitative contribution to inhibition potency. Bioactivity data on pIC50 values of 175 steroidal and 124 azaheterocyclic human aromatase inhibitors (AIs) were used for the 3D-QSAR analysis. For the quantitative description of the effects of the hydrophobic contact and nitrogen–heme–iron coordination on aromatase inhibition, the hydrophobicity density field model and the smallest dual descriptor Δf(r)S were introduced, respectively. The model revealed that hydrophobic contact and nitrogen–heme–iron coordination primarily determines inhibition potency of steroidal and azaheterocyclic AIs, respectively. Moreover, hydrogen bonds with key amino acid residues, in particular Asp309 and Met375, and interaction with the heme–iron are required for potent inhibition. Phe221 and Thr310 appear to be quite flexible and adopt different conformations according to a substituent at 4- or 6-position of steroids. Flexible docking results indicate that proper representation of the residues’ flexibility is critical for reasonable description of binding of the structurally diverse inhibitors. Our results provide a quantitative and mechanistic understanding of inhibitory activity of steroidal and azaheterocyclic AIs of relevance to adverse outcome pathway development and rational drug design.

7 alpha-substituted derivatives of androstenedione as inhibitors of estrogen biosynthesis.

7α-SUBSTITUTED DERIVATIVES OF ANDROSTENEDIONE AS INHIBITORS OF ESTROGEN BIOSYNTHESIS

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Syntheses and Qsar Studies of Benzylimidazole Derivatives and Benzylcarbazole As Potential Aromatase Inhibitors

Design, synthesis, biological activity evaluation and structure-activity relationships of new steroidal aromatase inhibitors. The case of C-ring and 7β substituted steroids

[Synthesis and Antifertility Activity of A-nor-5 Alpha-Androstane Derivatives].

Synthesis and antiproliferative activity of 7-substituted amide estradiol derivatives

QSAR of 19-substituted androstenedione analogs as aromatase inhibitors

Synthesis and 5 alpha-Reductase Inhibition Activity Evaluation of 3-Keto-4-aza-Delta(5)-androstene-17-oximido Derivatives

Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide.

Synthesis and Estrogen-Like Activity of Resveratrol Analogues

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors

Design, Synthesis and Biological Evaluation of Novel Androst-3,5-diene-3-carboxylic Acid Derivatives As Inhibitors of 5Α-Reductase Type 1 and 2

Syntheses of Some 17-Heterocyclic Substituted Androstene Derivatives as Inhibitors of Human 17α-Hydroxylase/C17,20-layse(P45017α)

Aromatase inhibition and inactivation

Synthesis, Characterization of a Series of Daidzein Derivatives As Selective Estrogen Receptor Modulator

Potent Aromatase Inhibitors and Molecular Mechanism of Inhibitory Action

Synthesis and biological evaluation of novel D-ring fused steroidal N(2)-substituted-1,2,3-triazoles

Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure.

3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein–ligand interactions

Synthesis of novel D-ring fused 7'-aryl-androstano[17,16-d][1,2,4] triazolo[1,5-a]pyrimidines.